Publications
By Year
Now showing items 3701-3720 of 5385 records
Objective Metabolomics Research.
Mika Ala-Korpela
CLINICAL CHEMISTRY - 01 Jan 2018
Study design and methods for the ACTIVity And TEchnology (ACTIVATE) trial.
Brigid M Lynch; Nga H Nguyen; Marina M Reeves; Melissa M Moore; Dori E Rosenberg; Michael J Wheeler; Terry Boyle; Jeff K Vallance; Christine M Friedenreich; Dallas R English
CONTEMPORARY CLINICAL TRIALS - 01 Jan 2018
Physical activity is positively associated with survival and quality of life among breast cancer survivors. Despite these benefits, the majority of breast cancer survivors are insufficiently active. The potential health benefits of reducing sedentary behaviour (sitting time) in this population have not been extensively investigated. The ACTIVATE Trial will evaluate the efficacy of an interventi...
Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Olga Montvida; Jonathan Shaw; John J Atherton; Frances Stringer; Sanjoy K Paul
DIABETES CARE - 01 Jan 2018
To explore temporal trends in antidiabetes drug (ADD) prescribing and intensification patterns, along with glycemic levels and comorbidities, and possible benefits of novel ADDs in delaying the need for insulin initiation in patients diagnosed with type 2 diabetes.Patients with type 2 diabetes aged 18-80 years, who initiated any ADD, were selected ( = 1,023,340) from the U.S. Centricity Electro...
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles M Atisso; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto G Cardona-Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev;
DIABETES, OBESITY & METABOLISM - 01 Jan 2018
The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 c...
Screening for diabetes prevention with diabetes risk scores - A balancing act.
Crystal Man Ying Lee; Vincent L Versace; Jonathan A Malo; Jonathan E Shaw; James A Dunbar; Stephen Colagiuri
DIABETES RESEARCH AND CLINICAL PRACTICE - 01 Jan 2018
To compare the diabetes prevention impact and cost of several screening scenarios for diabetes prevention programs with the scenario which included an oral glucose tolerance test (OGTT).We included 4864 participants of the Australian Diabetes, Obesity and Lifestyle study who were aged ≥40 years, did not have known diabetes at baseline, and attended the five year follow-up. The proportions of pa...
Prolonged uninterrupted sitting increases fatigue in type 2 diabetes.
Paddy C Dempsey; David W Dunstan; Robyn N Larsen; Gavin W Lambert; Bronwyn A Kingwell; Neville Owen
DIABETES RESEARCH AND CLINICAL PRACTICE - 01 Jan 2018
Fatigue is a prevalent, costly and disabling clinical complaint among those with type 2 diabetes. In a randomized crossover trial, prolonged uninterrupted sitting increased fatigue by 29% relative to days when sitting was regularly interrupted by brief activity-breaks. This may have implications for diabetes-related quality of life, occupational productivity and self-care.
Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans.
Rebecca K C Loh; Melissa F Formosa; Nina Eikelis; David A Bertovic; Mitchell J Anderson; Shane A Barwood; Shane Nanayakkara; Neale D Cohen; Andre La Gerche; Anne T Reutens; Kenneth S Yap; Thomas W Barber; Gavin W Lambert; Martin H Cherk; Stephen J Duffy; Bronwyn A Kingwell; Andrew L Carey
DIABETOLOGIA - 01 Jan 2018
Increasing brown adipose tissue (BAT) activity is a possible therapeutic strategy to increase energy expenditure and glucose and lipid clearance to ameliorate obesity and associated comorbidities. The thiazolidinedione (TZD) class of glucose-lowering drugs increase BAT browning in preclinical experimental models but whether these actions extend to humans in vivo is unknown. The aim of this stud...
The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases.
Hang T Ta; Nghia P Truong; Andrew K Whittaker; Thomas P Davis; Karlheinz Peter
EXPERT OPINION ON DRUG DELIVERY - 01 Jan 2018
Vascular-targeted drug delivery is a promising approach for the treatment of atherosclerosis, due to the vast involvement of endothelium in the initiation and growth of plaque, a characteristic of atherosclerosis. One of the major challenges in carrier design for targeting cardiovascular diseases (CVD) is that carriers must be able to navigate the circulation system and efficiently marginate to...
Mechanisms of the Improvement in Peak VO With Exercise Training in Heart Failure With Reduced or Preserved Ejection Fraction.2
Wesley J Tucker; Cecilia C Lijauco; Christopher M Hearon; Siddhartha S Angadi; Michael D Nelson; Satyam Sarma; Shane Nanayakkara; André La Gerche; Mark J Haykowsky
HEART, LUNG & CIRCULATION - 01 Jan 2018
Heart failure (HF) is a major health care burden associated with high morbidity and mortality. Approximately 50% of HF patients have reduced ejection fraction (HFrEF) while the remainder of patients have preserved ejection fraction (HFpEF). A hallmark of both HF phenotypes is dyspnoea upon exertion and severe exercise intolerance secondary to impaired oxygen delivery and/or use by exercising sk...
Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form?
Murray Esler; Gavin Lambert; Markus Schlaich; John Dixon; Carolina Ika Sari; Elisabeth Lambert
HYPERTENSION (DALLAS, TEX. : 1979) - 01 Jan 2018
Mesoscale Nanoparticles: An Unexpected Means for Selective Therapeutic Targeting of Kidney Diseases!
May Lin Yap; Xiaowei Wang; Geoffrey A Pietersz; Karlheinz Peter
HYPERTENSION (DALLAS, TEX. : 1979) - 01 Jan 2018
Response to comments by Hoyer and Brinks (2017) on: 'Diabetes incidence and projections from prevalence surveys in Samoa over 1978-2013'.
Sophia Lin; Take Naseri; Christine Linhart; Stephen Morrell; Richard Taylor; Stephen T McGarvey; Paul Zimmet
INTERNATIONAL JOURNAL OF PUBLIC HEALTH - 01 Jan 2018
Early life exposure to Chinese famine modifies the association between hypertension and cardiovascular disease.
Zumin Shi; Stephen J Nicholls; Anne W Taylor; Dianna J Magliano; Sarah Appleton; Paul Zimmet
JOURNAL OF HYPERTENSION - 01 Jan 2018
Studies have shown that famine exposure during early life may increase the risk of cardiovascular disease (CVD), hypertension, and diabetes during adulthood. We aimed to assess whether exposure to the Chinese famine (1959-1961) modifies the association between hypertension and CVD.We investigated data of 5772 adults born between 1954 and 1964 from the China Health and Retirement Longitudinal St...
Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment.
U Flierl; T L Nero; B Lim; R K Andrews; M W Parker; E E Gardiner; K Peter
JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH - 01 Jan 2018
Highlights from the HTLV-1 symposium at the 2017 Australasian HIV and AIDS Conference held jointly with the 2017 Australasian Sexual Health Conference, November 2017, Canberra, Australia.
Lloyd Einsiedel; Damian Purcell; Shane Schinke; Katelin Haynes; Graham P Taylor; Fabiola Martin
JOURNAL OF VIRUS ERADICATION - 01 Jan 2018
We are pleased to report on the inaugural HTLV-1 symposium at the 2017 Australasian HIV and AIDS Conference joint with 2017 Australasian Sexual Health Conference in Canberra, Australia. Our understanding of HTLV-1 epidemiology, pathogenesis, laboratory diagnostics and treatment options for HTLV-1 diseases has advanced tremendously over the last 40 years. However, the awareness of healthcare pro...
Biatrial Electrical and Structural Atrial Changes in Heart Failure: Electroanatomic Mapping in Persistent Atrial Fibrillation in Humans.
Sandeep Prabhu; Aleksandr Voskoboinik; Alex J A McLellan; Kah Y Peck; Bhupesh Pathik; Chrishan J Nalliah; Geoff R Wong; Sonia M Azzopardi; Geoffrey Lee; Justin Mariani; Liang-Han Ling; Andrew J Taylor; Jonathan M Kalman; Peter M Kistler
JACC. CLINICAL ELECTROPHYSIOLOGY - 01 Jan 2018
This study sought to characterize the biatrial substrate in heart failure (HF) and persistent atrial fibrillation (PeAF).Atrial fibrillation (AF) and HF frequently coexist; however, the contribution of HF to the biatrial substrate in PeAF is unclear.Consecutive patients with PeAF and normal left ventricular (NLV) systolic function (left ventricular ejection fraction [LVEF] >55%) or idiopathic c...
Transient Rotor Activity During Prolonged 3-Dimensional Phase Mapping in Human Persistent Atrial Fibrillation.
Bhupesh Pathik; Jonathan M Kalman; Tomos Walters; Pawel Kuklik; Jichao Zhao; Andrew Madry; Sandeep Prabhu; Chrishan Nalliah; Peter Kistler; Geoffrey Lee
JACC. CLINICAL ELECTROPHYSIOLOGY - 01 Jan 2018
This study sought to validate a 3-dimensional (3D) phase mapping system and determine the distribution of dominant propagation patterns in persistent atrial fibrillation (AF).Currently available systems display phase as simplified 2-dimensional maps. We developed a novel 3D phase mapping system that uses the 3D location of basket catheter electrodes and the patient's 3D left atrial surface geom...
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney; Mark E Cooper; Ilkka Tikkanen; Egon Pfarr; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Søren S Lund
KIDNEY INTERNATIONAL - 01 Jan 2018
Sodium glucose cotransporter 2 (SGLT2) inhibitors reduce HbA1c, blood pressure, and weight in patients with type 2 diabetes. To investigate the effect of renal function on reductions in these parameters with the SGLT2 inhibitor empagliflozin, we assessed subgroups by baseline estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease) in pooled data from five 24-week tria...
Live Metabolic Profile Analysis of Zebrafish Embryos Using a Seahorse XF 24 Extracellular Flux Analyzer.
Simon T Bond; Kevin A McEwen; Prusothman Yoganantharajah; Yann Gibert
METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) - 01 Jan 2018
The Agilent Seahorse Extracellular Flux Analyzer can be used to measure the oxygen consumption rate (OCR) and extra cellular acidification rate (ECAR), from which mitochondrial bioenergetics measurements can be determined including basal respiration, respiration due to ATP turnover, uncoupled respiration/proton leak, and maximum respiration. This novel method demonstrates how to use a Seahorse ...
Beyond gut feelings: how the gut microbiota regulates blood pressure.
Francine Z Marques; Charles R Mackay; David M Kaye
NATURE REVIEWS. CARDIOLOGY - 01 Jan 2018
Hypertension is the leading risk factor for heart disease and stroke, and is estimated to cause 9.4 million deaths globally every year. The pathogenesis of hypertension is complex, but lifestyle factors such as diet are important contributors to the disease. High dietary intake of fruit and vegetables is associated with reduced blood pressure and lower cardiovascular mortality. A critical relat...
Show more...